Cargando…

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis

Detalles Bibliográficos
Autores principales:	Velásquez, Gustavo E., Nahid, Payam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2023
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111973/ https://www.ncbi.nlm.nih.gov/pubmed/36630555 http://dx.doi.org/10.1164/rccm.202212-2262ED

Ejemplares similares

Digital Health: The Promise and Peril
por: Superina, Stefan, et al.
Publicado: (2022)

Hybrid working in radiology: the promise and the perils
por: Nicholson, Patrick
Publicado: (2022)

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
por: Bateson, Anna, et al.
Publicado: (2022)

Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
por: Lyons, Michael A.
Publicado: (2021)

Pretomanid for tuberculosis treatment: an update for clinical purposes
por: Occhineri, Sara, et al.
Publicado: (2022)

The promise and potential peril of at-home oral cancer testing
por: Lingen, Mark W.
Publicado: (2023)

ChatGPT for scientific paper writing—promises and perils
por: He, Shijun, et al.
Publicado: (2023)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
por: Timm, Juliano, et al.
Publicado: (2023)

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
por: Li, Si-Yang, et al.
Publicado: (2017)

1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project
por: Goswami, Neela, et al.
Publicado: (2021)

Use of Isoniazid Monotherapy in Comparison to Rifamycin-Based Regimen for the Treatment of Patients With Latent Tuberculosis: A Systematic Review
por: Shahid, Noor ul ain, et al.
Publicado: (2022)

Measuring effectiveness of drugs in observational databanks: promises and perils
por: Krishnan, Eswar, et al.
Publicado: (2004)

The promises and perils of the neuroscience of creativity
por: Abraham, Anna
Publicado: (2013)

Moral outrage: Promise or peril?
por: Rushton, Cynda Hylton, et al.
Publicado: (2020)

The promise and peril of health systems
por: Kronick, Richard
Publicado: (2020)

Perils and promise of online exams
por: Schultz, Madeleine, et al.
Publicado: (2022)

The Promise and Perils of CNS Drug Delivery: A Video Debate
por: Gendelman, Howard E., et al.
Publicado: (2008)

Michigan’s Peril
Publicado: (1900)

Canada’s Peril
Publicado: (1903)

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
por: Li, Si-Yang, et al.
Publicado: (2023)

The promise and peril of universal health care
por: Bloom, David E., et al.
Publicado: (2018)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Characterization of the Rifamycin-Degrading Monooxygenase From Rifamycin Producers Implicating Its Involvement in Saliniketal Biosynthesis
por: Zheng, Xiao-Fu, et al.
Publicado: (2020)

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
por: Imperial, Marjorie Z., et al.
Publicado: (2018)

Cyclooxygenase-2 inhibitors: promise or peril?
por: Mengle-Gaw, Laurel J, et al.
Publicado: (2002)

The promise and perils of HDAC inhibitors in neurodegeneration
por: Didonna, Alessandro, et al.
Publicado: (2015)

The promise and peril of sexual harassment programs
por: Dobbin, Frank, et al.
Publicado: (2019)

Digital health promotion: promise and peril
por: Koh, Amanda, et al.
Publicado: (2021)

Promise and Perils of Telehealth in the Current Era
por: Mahtta, Dhruv, et al.
Publicado: (2021)

The Peril of the University of Texas
Publicado: (1917)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis
por: Li, Hanbin, et al.
Publicado: (2019)

The Promise and Peril of Genomic Screening in the General Population
por: Adams, Michael C., et al.
Publicado: (2015)

Male reproductive hormones in patients treated with pretomanid
por: Boekelheide, K., et al.
Publicado: (2022)

Enhancing risk stratification for life‐threatening ventricular arrhythmias in dilated cardiomyopathy: the peril and promise of precision medicine
por: Asatryan, Babken, et al.
Publicado: (2020)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro
por: Hu, Minghao, et al.
Publicado: (2020)

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hud9n6pm3gtaj79nrd986cvt5p